<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of idiopathic nephrotic syndrome in children</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of idiopathic nephrotic syndrome in children</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of idiopathic nephrotic syndrome in children</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patrick Niaudet, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tej K Mattoo, MD, DCH, FRCP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 01, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The nephrotic syndrome (NS) is observed in children with kidney diseases associated with increased permeability of the glomerular filtration barrier. Idiopathic NS is the most common form of NS in children. It is characterized by diffuse foot process effacement on electron microscopy and any of a variety of findings on light microscopy that include minimal changes, focal segmental glomerulosclerosis (FSGS), and mesangial proliferation. (See  <a class="medical medical_review" href="/d/html/6101.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of nephrotic syndrome in children", section on 'Primary nephrotic syndrome'</a>.)</p><p>An overview of the treatment of idiopathic NS in children is presented here. The etiology, clinical manifestations, and diagnosis of NS in children are discussed separately. (See  <a class="medical medical_review" href="/d/html/6101.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of nephrotic syndrome in children"</a>.)</p><p>The management of adults with NS is also discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/3046.html" rel="external">"Minimal change disease: Etiology, clinical features, and diagnosis in adults"</a> and  <a class="medical medical_review" href="/d/html/3049.html" rel="external">"Focal segmental glomerulosclerosis: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/3045.html" rel="external">"Minimal change disease: Treatment in adults"</a> and  <a class="medical medical_review" href="/d/html/3100.html" rel="external">"Focal segmental glomerulosclerosis: Treatment and prognosis"</a> and  <a class="medical medical_review" href="/d/html/3051.html" rel="external">"Membranous nephropathy: Treatment and prognosis"</a>.)</p><p class="headingAnchor" id="H3168119083"><span class="h1">DEFINITION</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nephrotic syndrome (NS)</strong> is defined as a condition classically characterized by all three of the following features (see  <a class="medical medical_review" href="/d/html/6101.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of nephrotic syndrome in children"</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nephrotic range proteinuria – Urine protein excretion &gt;50 mg/kg per day or a spot urine sample with a ratio (U<sub>P</sub>/U<sub>Cr</sub>) &gt;3 mg of protein per mg of creatinine (see  <a class="medical medical_review" href="/d/html/6101.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of nephrotic syndrome in children", section on 'Confirming the diagnosis'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hypoalbuminemia – Serum albumin &lt;3 g/dL (30 g/L)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Edema</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Steroid-resistant NS (SRNS)</strong> is defined as NS resistant to steroid therapy, defined by the absence of complete remission after an initial course of daily <a class="drug drug_pediatric" data-topicid="12725" href="/d/drug information/12725.html" rel="external">prednisone</a> therapy at a dose of 60 mg/m<sup>2 </sup>per day [<a href="#rid1">1,2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complete remission</strong> is resolution of proteinuria defined as a urine protein-to-creatinine ratio (UPCR) based on a first morning void or 24-hour collection of ≤20 mg/mmol (0.2 mg protein/mg creatinine) or urine dipstick readings of negative or trace protein on three consecutive days.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Partial remission </strong>is a decrease in proteinuria with a UPCR based on first morning void or 24-hour urine sample of &gt;20 but &lt;200 mg/mmol and, if available, serum albumin ≥30 g/L.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Relapse</strong> is the recurrence of nephrotic-range proteinuria following either complete or partial remission.</p><p></p><p class="headingAnchor" id="H2"><span class="h1">MANAGEMENT OVERVIEW</span></p><p class="headingAnchor" id="H534161321"><span class="h2">Steroid therapy</span><span class="headingEndMark"> — </span>Most children with idiopathic NS have minimal change disease (MCD), which is generally responsive to steroid therapy [<a href="#rid3">3</a>]. MCD is the underlying cause of NS in approximately 75 to 80 percent of pediatric cases and clinical findings are highly predictable in differentiating MCD from other forms of NS [<a href="#rid4">4,5</a>]. As a result, empiric steroid therapy is typically initiated in patients who are likely to have MCD based on clinical criteria without histological confirmation by kidney biopsy. In addition, some patients with focal segmental glomerular sclerosis (FSGS), which accounts for another 15 to 20 percent of idiopathic NS cases in children, may respond to steroid therapy. (See <a class="local">'Empiric steroid therapy versus kidney biopsy'</a> below and  <a class="medical medical_review" href="/d/html/6101.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of nephrotic syndrome in children", section on 'Primary nephrotic syndrome'</a>.)</p><p>Clinical experience has demonstrated that the response to initial steroid therapy rather than the histologic features seen on kidney biopsy is a better predictor of long-term prognosis. As a result, patients with idiopathic NS can be defined by their response to steroid therapy as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Steroid-sensitive NS (SSNS) – More than 90 percent of patients who respond to steroid therapy have MCD [<a href="#rid1">1</a>]; FSGS is most commonly seen in the remaining patients [<a href="#rid1">1</a>]. Almost all patients with SSNS have an excellent outcome, with few patients developing late steroid resistance or end-stage kidney disease (ESKD) or chronic kidney disease. (See <a class="local">'Steroid-sensitive nephrotic syndrome'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Steroid-resistant NS (SRNS) – Ten to 20 percent of children with idiopathic NS fail to respond to initial empirical steroid therapy. Kidney biopsy shows minimal changes in one-fourth of them and FSGS or mesangial proliferation in most of the remaining patients who are biopsied. These children are at increased risk for developing ESKD [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/d/html/16711.html" rel="external">"Steroid-resistant nephrotic syndrome in children: Etiology"</a>.)</p><p></p><p class="headingAnchor" id="H1790702211"><span class="h2">Nonimmune general measures</span><span class="headingEndMark"> — </span>General measures are focused on preventing or minimizing complications due to the underlying NS and are discussed in greater detail separately (see  <a class="medical medical_review" href="/d/html/6113.html" rel="external">"Symptomatic management of nephrotic syndrome in children"</a> and  <a class="medical medical_review" href="/d/html/6102.html" rel="external">"Complications of nephrotic syndrome in children"</a>).</p><p>These include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infection control</strong> (see  <a class="medical medical_review" href="/d/html/6113.html" rel="external">"Symptomatic management of nephrotic syndrome in children", section on 'Infection'</a> and  <a class="medical medical_review" href="/d/html/6102.html" rel="external">"Complications of nephrotic syndrome in children", section on 'Infection'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Prevention of infection with vaccination with 23-valent polysaccharide (<a class="drug drug_pediatric" data-topicid="12948" href="/d/drug information/12948.html" rel="external">PPSV23</a>) pneumococcal and varicella vaccines if not previously immunized, as patients with NS are at increased risk of infection. However, live vaccinations should be avoided during relapse and while on daily immunosuppressive medications.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Identification and treatment of suspected infections (pneumonia, cellulitis, sepsis, peritonitis) as these patients are immunosuppressed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Management of <strong>edema and anasarca</strong> with avoidance of excessive fluid intake, moderate restriction of dietary salt, elevation of extremities, and judicious use of diuretics. (See  <a class="medical medical_review" href="/d/html/6113.html" rel="external">"Symptomatic management of nephrotic syndrome in children", section on 'Edema'</a>.)</p><p></p><p class="bulletIndent1">In patients with severe anasarca or edema, active mobilization of fluid can be undertaken with intravenous administration of a loop diuretic in conjunction with salt-poor 25 percent albumin. (See  <a class="medical medical_review" href="/d/html/6113.html" rel="external">"Symptomatic management of nephrotic syndrome in children", section on 'Patients with edema and intravascular hypovolemia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prevention of <strong>venous thromboembolism</strong> by avoiding restriction of patient mobilization and intravascular hypovolemia. (See  <a class="medical medical_review" href="/d/html/6113.html" rel="external">"Symptomatic management of nephrotic syndrome in children", section on 'Hypercoagulability'</a> and  <a class="medical medical_review" href="/d/html/6102.html" rel="external">"Complications of nephrotic syndrome in children", section on 'Thromboembolism'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Maintenance of adequate <strong>protein intake</strong> (130 to 140 percent of the recommended daily allowance).</p><p></p><p class="headingAnchor" id="H4"><span class="h1">INITIAL THERAPY</span></p><p class="headingAnchor" id="H1431707243"><span class="h2">Empiric steroid therapy versus kidney biopsy</span><span class="headingEndMark"> — </span>As noted above, the most common cause of pediatric NS is idiopathic NS, primarily minimal change disease (MCD), which is generally responsive to steroid therapy [<a href="#rid3">3</a>]. As a result, we initiate empiric steroid therapy in all patients with a high probability of having MCD on clinical criteria without confirmation of the diagnosis by kidney biopsy. This approach is consistent with guidelines from a number of organizations globally [<a href="#rid6">6-8</a>]. Thus, empiric therapy can be started in patients who fulfill <strong>all</strong> of the following clinical criteria that is predictive of MCD [<a href="#rid1">1,9,10</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Age older than 1 year and younger than 10 years of age</p><p class="bulletIndent1"><span class="glyph">●</span>None of the following findings: hypertension, gross hematuria, marked elevation in serum creatinine</p><p class="bulletIndent1"><span class="glyph">●</span>Normal complement levels</p><p class="bulletIndent1"><span class="glyph">●</span>No extrarenal symptoms, such as malar rash or purpura</p><p></p><p>Although steroid therapy is often started immediately following the diagnosis of NS, it should be stressed that spontaneous remission occurs in 5 percent of cases within one or two weeks. Therefore, the initiation of steroid therapy may be delayed for a few days or a week [<a href="#rid11">11</a>].</p><p>In children who do not meet these criteria, a kidney biopsy is recommended because of the increased prevalence of other causes of NS. In these patients, therapeutic decisions are based on the histologic diagnosis. (See  <a class="medical medical_review" href="/d/html/6101.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of nephrotic syndrome in children"</a> and  <a class="medical medical_review" href="/d/html/3100.html" rel="external">"Focal segmental glomerulosclerosis: Treatment and prognosis"</a> and  <a class="medical medical_review" href="/d/html/3058.html" rel="external">"Membranoproliferative glomerulonephritis: Treatment and prognosis"</a> and  <a class="medical medical_review" href="/d/html/3051.html" rel="external">"Membranous nephropathy: Treatment and prognosis"</a> and  <a class="medical medical_review" href="/d/html/3046.html" rel="external">"Minimal change disease: Etiology, clinical features, and diagnosis in adults", section on 'Minimal change variants'</a>.)</p><p class="headingAnchor" id="H1278299190"><span class="h2">Initial steroid course</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial course</strong> – For children with NS who are likely to have MCD, initial treatment is with oral <a class="drug drug_pediatric" data-topicid="12725" href="/d/drug information/12725.html" rel="external">prednisone</a> at a dose of 60 mg/m<sup>2</sup> per day (maximum of 60 mg/day) [<a href="#rid2">2</a>]. This dose can be given once daily or divided into two doses administered twice a day. After initiation of steroid therapy, patients and their parents/caregivers are taught to monitor urine protein levels by urine dipstick [<a href="#rid12">12</a>]. (See <a class="local">'Monitoring'</a> below.)</p><p></p><p class="bulletIndent1">Complete remission is defined by the disappearance of proteinuria. Of the children who go into remission, approximately 90 percent of children will do so within the first four weeks of oral <a class="drug drug_pediatric" data-topicid="12725" href="/d/drug information/12725.html" rel="external">prednisone</a> therapy and the remaining 10 percent respond after an additional two more weeks of steroid therapy  (<a class="graphic graphic_figure graphicRef58623" href="/d/graphic/58623.html" rel="external">figure 1</a>) [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Slow responders</strong> – For patients who remain proteinuric after four weeks, our practice is to administer three intravenous pulses of <a class="drug drug_pediatric" data-topicid="12601" href="/d/drug information/12601.html" rel="external">methylprednisolone</a> (1000 mg/1.73 m<sup>2</sup>) every other day rather than an additional course of oral <a class="drug drug_pediatric" data-topicid="12725" href="/d/drug information/12725.html" rel="external">prednisone</a> used at other centers [<a href="#rid2">2,13,14</a>].</p><p></p><p class="bulletIndent1">The five-year outcome of our protocol, using daily oral <a class="drug drug_pediatric" data-topicid="12725" href="/d/drug information/12725.html" rel="external">prednisone</a> therapy and <a class="drug drug_pediatric" data-topicid="12601" href="/d/drug information/12601.html" rel="external">methylprednisolone</a> pulses for refractory patients, was assessed in 188 children with NS [<a href="#rid14">14</a>]. Of the 174 patients who were steroid responsive, 164 children (93 percent) were responsive within the four weeks of initiating therapy, and 10 patients received intravenous methylprednisolone, which resulted in remission. At last follow-up, 36 of the 174 patients (21 percent) remained relapse-free. This regimen, compared with prolongation of daily administration of steroids, may produce remission more quickly in the few patients who require additional steroid therapy in the second month after diagnosis.</p><p></p><p class="bulletIndent1">Other centers do not administer intravenous <a class="drug drug_pediatric" data-topicid="12601" href="/d/drug information/12601.html" rel="external">methylprednisolone</a> as standard practice in initially refractory patients and may use one of the following alternate approaches in patients who are not in remission after an initial four-week course of daily steroid therapy:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Biopsy patients without administering the three pulses of <a class="drug drug_pediatric" data-topicid="12601" href="/d/drug information/12601.html" rel="external">methylprednisolone</a>, as there is an increased likelihood that they have another glomerular disease that may not be responsive to additional steroid therapy. Histologic findings guide further therapeutic decisions. (See  <a class="medical medical_review" href="/d/html/6101.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of nephrotic syndrome in children"</a> and  <a class="medical medical_review" href="/d/html/16711.html" rel="external">"Steroid-resistant nephrotic syndrome in children: Etiology"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Continue daily steroid therapy for another two to four weeks because an additional 10 percent of steroid-responsive patients will respond after four weeks of therapy [<a href="#rid1">1</a>]. Patients who fail to respond to a maximum eight weeks of daily steroid therapy are considered steroid resistant [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/d/html/6101.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of nephrotic syndrome in children"</a> and <a class="local">'No remission: Steroid-resistant nephrotic syndrome'</a> below.)</p><p></p><p class="headingAnchor" id="H2650847017"><span class="h2">Remission: Steroid-sensitive nephrotic syndrome</span><span class="headingEndMark"> — </span>With the onset of remission, we continue <a class="drug drug_pediatric" data-topicid="12725" href="/d/drug information/12725.html" rel="external">prednisone</a> at the same daily dose for 30 days and then switch to alternate-day therapy (at the same daily dose). Alternate-day therapy is tapered over a one- to two-month period.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of therapy</strong> – Although there is general agreement on the initial dosing of <a class="drug drug_pediatric" data-topicid="12725" href="/d/drug information/12725.html" rel="external">prednisone</a> of 60 mg/m<sup>2</sup> or 2 mg/kg per day, there is no consensus on the total duration of initial steroid therapy following the onset of remission, as the optimal duration of therapy for reducing subsequent relapses remains uncertain [<a href="#rid15">15</a>]. As discussed above, in our practice, prednisone therapy is continued at the same daily dose for 30 days at the onset of remission and then switched to alternate-day therapy at a dose of 40 mg/m<sup>2</sup> (maximum dose 60 mg every other day) for the next four weeks and then discontinued.</p><p></p><p class="bulletIndent1">Other published steroid regimens include the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Children's Nephrotic Syndrome Consensus, a group of pediatric nephrologists from the southeast and midwest sections of the United States, published guidelines in 2009 that recommended initial steroid therapy of oral <a class="drug drug_pediatric" data-topicid="12725" href="/d/drug information/12725.html" rel="external">prednisone</a> of 2 mg/kg per day for six weeks, followed by alternate-day prednisone of 1.5 mg/kg for an additional six weeks [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The 2012 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommended initial <a class="drug drug_pediatric" data-topicid="12725" href="/d/drug information/12725.html" rel="external">prednisone</a> therapy of 60 mg/m<sup>2</sup> or 2 mg/kg per day for four to six weeks (maximum dose of 60 mg/day), followed by alternate-day prednisone of 40 mg/m<sup>2</sup> or 1.5 mg/kg (maximum dose of 40 mg/day) and tapered over two to five months [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The 2014 Canadian Society of Nephrology (CSN) guidelines recommended initial <a class="drug drug_pediatric" data-topicid="12725" href="/d/drug information/12725.html" rel="external">prednisone</a> therapy of 2 mg/kg per day beyond 12 weeks and up to six months [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The 2021 Indian Society of Pediatric Nephrology guidelines recommend that therapy for the initial episode should comprise <a class="drug drug_pediatric" data-topicid="12723" href="/d/drug information/12723.html" rel="external">prednisolone</a> at a dose of 60 mg/m<sup>2</sup>/day (2 mg/kg/day, maximum 60 mg administered in one to two divided doses) for six weeks, followed by 40 mg/m<sup>2</sup> (1.5 mg/kg, maximum 40 mg as a single morning dose) on alternate days for the next six weeks, and then discontinued [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1">The KDIGO and CSN guidelines adopted a long initial course of steroids based on earlier systematic reviews that showed that initial therapy of at least three to seven months, including periods of daily and alternate-day therapy, reduced the risk of subsequent relapses [<a href="#rid7">7,17</a>]. However, a subsequent systematic review concluded that older, high-risk-of-bias studies overestimated the effect of longer course therapy as compared with subsequent studies of higher quality. Two randomized controlled trials at low risk of bias from Japan and India showed that extending initial therapy beyond 8 to 12 weeks does not influence the time to first relapse or the risk of frequent relapses at one to two years' follow-up [<a href="#rid18">18,19</a>]. In addition, a more recent clinical trial of 237 children (age range from 1 to 14 years) with a first episode of steroid-sensitive NS (SSNS) reported similar outcome between an extended 16-week course and a standard 8-week course of <a class="drug drug_pediatric" data-topicid="12725" href="/d/drug information/12725.html" rel="external">prednisone</a> regarding time to first relapse and the incidence of frequently relapsing NS (53 versus 50 percent), steroid-dependent NS (42 versus 44 percent), or requirement for alternative immunosuppressive treatment (54 versus 56 percent) [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1">As a result of the available evidence, treatment durations of two or three months are recommended for the management of the first episode of SSNS rather than longer durations [<a href="#rid21">21,22</a>]. Slow tapering to avoid adrenal suppression may be important to maintain long-term remission as demonstrated in a small study that reported moderate to severe post-prednisone adrenal suppression was associated with an increased risk of relapse [<a href="#rid23">23</a>].</p><p></p><p class="headingAnchor" id="H2990964491"><span class="h2">No remission: Steroid-resistant nephrotic syndrome</span><span class="headingEndMark"> — </span>Ten to 15 percent of children will fail to respond to steroid therapy and will continue to have persistent proteinuria after completion of the initial steroid therapy [<a href="#rid13">13,14</a>]. Evaluation for these children who have steroid-resistant NS (SRNS) is focused on identifying the etiology, as therapeutic decisions are based on the underlying cause. Evaluation may include screening for genetic disorders and/or kidney biopsy. Steroid therapy is weaned and additional therapeutic management is decided on the evaluations for SRNS.</p><p>The causes and management of SRNS in children are discussed separately. (See  <a class="medical medical_review" href="/d/html/6101.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of nephrotic syndrome in children"</a> and  <a class="medical medical_review" href="/d/html/16711.html" rel="external">"Steroid-resistant nephrotic syndrome in children: Etiology"</a> and  <a class="medical medical_review" href="/d/html/117983.html" rel="external">"Steroid-resistant nephrotic syndrome in children: Management"</a>.)</p><p class="headingAnchor" id="H2729716840"><span class="h2">No additional advantage with cyclosporine as initial therapy</span><span class="headingEndMark"> — </span>Increasing initial immunosuppression by adding <a class="drug drug_pediatric" data-topicid="13193" href="/d/drug information/13193.html" rel="external">cyclosporine</a> to steroid therapy has been proposed as a way to reduce the relapse rate. However, the addition of cyclosporine does not alter the two-year relapse rate, and the initial combination of cyclosporine and <a class="drug drug_pediatric" data-topicid="12725" href="/d/drug information/12725.html" rel="external">prednisone</a> compared with prednisone alone results in a greater number of side effects [<a href="#rid24">24,25</a>]. As a result, steroids alone are used as the initial therapy for childhood idiopathic NS.</p><p class="headingAnchor" id="H174702423"><span class="h2">Outcome based on response</span><span class="headingEndMark"> — </span>Outcome of response is based on published observational case series [<a href="#rid9">9,26</a>]. The majority of children who respond to steroid therapy with complete remission do well as noted by the following case series, whereas children who fail to respond to steroid therapy (SRNS) have a greater risk of developing end-stage kidney disease (ESKD).</p><p class="bulletIndent1"><span class="glyph">●</span>In a multicenter study of 389 children with biopsy-proven MCD diagnosed between 1967 and 1976, over 90 percent responded with complete remission to initial steroid therapy [<a href="#rid9">9</a>]. Approximately one-third of these patients had frequently relapsing disease, defined as four or more relapses per year or two or more relapses in the initial six months after diagnosis. At eight-year follow-up, 80 percent of patients remained in remission. Five of the 29 patients who were steroid resistant progressed to ESKD. Deaths occurring in less than 2 percent of patients were from complications related to nephrosis (eg, peritonitis).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a second case series of 631 children diagnosed with idiopathic NS treated between 1993 and 2016, approximately 93 percent of patients were responsive to an initial course of steroids of which approximately one-quarter remained in complete remission [<a href="#rid26">26</a>]. Approximately 60 percent of the cohort maintained long-term remission throughout childhood, but approximately one-third of the patients had frequently relapsing disease. Only 2 percent of the original cohort progressed to ESKD, including seven patients who were initially steroid sensitive and three who were steroid resistant. There were no deaths reported during the duration of the study period.</p><p></p><p class="headingAnchor" id="H9"><span class="h1">STEROID-SENSITIVE NEPHROTIC SYNDROME</span><span class="headingEndMark"> — </span>The majority of children with idiopathic NS have minimal change disease (MCD) and will attain complete remission with an initial course of steroid therapy. However, 80 percent of steroid-responsive patients will experience one or more subsequent relapses, which typically remain responsive (sensitive) to steroid therapy [<a href="#rid3">3,9,14,27</a>]. The risk of relapse is greater in children aged less than five years at onset. Management for patients with steroid-sensitive NS (SSNS) is focused on early detection and treatment of any relapse to reduce the risk of complications associated with NS. (See <a class="local">'Frequently relapsing/steroid-dependent nephrotic syndrome'</a> below.)</p><p class="headingAnchor" id="H3362372406"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>Once a patient responds to steroid therapy, ongoing monitoring for proteinuria is required to detect relapses early and initiate therapy to prevent significant fluid accumulation (edema) and minimize the complications associated with NS. (See  <a class="medical medical_review" href="/d/html/6102.html" rel="external">"Complications of nephrotic syndrome in children"</a>.)</p><p>Patients and their parents/caregivers are taught to routinely measure body weight as well as continue to monitor urine protein levels by urine dipstick on a daily basis [<a href="#rid12">12</a>]. Increased urine protein concentration typically provides the first indication of a relapse. When this occurs, the family/caregiver should call their health care provider for instructions regarding management.</p><p class="headingAnchor" id="H81224482"><span class="h2">Initial or infrequent relapse</span><span class="headingEndMark"> — </span>With the first initial relapse or for infrequent relapses, steroid therapy is typically administered at a dose of 60 mg/m<sup>2</sup> or 2 mg/kg per day (maximum dose of 60 mg/day). The length of steroid therapy varies among pediatric nephrologists. In our practice, daily <a class="drug drug_pediatric" data-topicid="12725" href="/d/drug information/12725.html" rel="external">prednisone</a> is given until proteinuria has disappeared for at least three consecutive days. Alternate-day therapy is then begun, and the dose tapered to 15 to 20 mg/m<sup>2</sup> every other day for another four weeks and then discontinued.</p><p>Our approach is similar to the one used by the Children's Nephrotic Syndrome Consensus group, which suggests treating the first relapse or infrequent relapse with <a class="drug drug_pediatric" data-topicid="12725" href="/d/drug information/12725.html" rel="external">prednisone</a> therapy of 2 mg/kg per day (maximum dose of 60 mg/day) until the proteinuria has resolved for three consecutive days [<a href="#rid6">6</a>]. At that point, alternate-day prednisone is administered at a dose of 1.5 mg/kg per day (maximum dose of 45 mg/day) for four weeks.</p><p>However, the optimal management of relapses for children who are infrequent relapsers is uncertain. Since there are known adverse effects of prolonged steroid therapy, research including the following studies are focused on finding effective but shorter course of steroid therapy.</p><p class="bulletIndent1"><span class="glyph">●</span>A single-center open-label trial of 117 children with NS reported patients treated with a short course of <a class="drug drug_pediatric" data-topicid="12723" href="/d/drug information/12723.html" rel="external">prednisolone</a> (40 mg/m<sup>2</sup> on alternate days for two weeks) compared with those managed by a standard regimen (40 mg/m<sup>2</sup> on alternate days for four weeks) had a similar rate of frequent relapse/steroid dependence at 12 months of follow-up (24 versus 23 percent) [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A second open-label clinical trial of 78 children (ages 3 to 17 years) with SSNS who achieved remission after five days of consecutive steroids following a relapse provided additional support for a shorter course of alternative day steroids after remission is induced [<a href="#rid29">29</a>]. In this cohort, patients assigned to a short course of alternate day steroids (18 doses of 40 mg/m<sup>2</sup> of <a class="drug drug_pediatric" data-topicid="12725" href="/d/drug information/12725.html" rel="external">prednisone</a> over 36 days) and those assigned to a more prolonged alternate day course (40 mg/m<sup>2</sup> tapered over 72 days by steps of 6 doses) had similar rates of relapse at six months (42 versus 58 percent).</p><p></p><p>Additional large clinical trials are needed to determine the optimal management of children with SSNS who have infrequent relapses to minimize steroid exposure without increasing the risk of relapse.</p><p class="headingAnchor" id="H12"><span class="h2">Frequently relapsing/steroid-dependent nephrotic syndrome</span><span class="headingEndMark"> — </span>Approximately 25 to 30 percent of steroid-responsive patients will develop frequently relapsing NS, defined as four or more relapses per year or two or more relapses in the initial six months after diagnosis [<a href="#rid9">9,14</a>]. In addition, there is a group of patients who are steroid dependent (defined as relapsing during taper or within two weeks of discontinuation of steroid therapy). In our practice, for patients who relapse within one month after discontinuing therapy or while <a class="drug drug_pediatric" data-topicid="12725" href="/d/drug information/12725.html" rel="external">prednisone</a> is decreased (steroid-dependent), daily prednisone therapy is reinitiated until remission, 40 to 60 mg/m<sup>2 </sup>(maximum dose 60 mg), until proteinuria has disappeared for four to five days, followed by alternate-day therapy with tapering by 15 to 20 mg/m<sup>2</sup> every other day to the patient's steroid threshold (ie, the dose at which the relapse has occurred) [<a href="#rid30">30</a>]. This regimen is continued for 12 to 18 months. Although the management approach is similar, a distinction between frequent relapsers and steroid-dependent patients should be made, if possible, because frequently relapsing NS seems to have a slightly better prognosis regarding response to steroid-sparing agents and long-term remission [<a href="#rid31">31</a>].</p><p>Although children with frequently relapsing or steroid-dependent NS are at risk for steroid toxicity, <a class="drug drug_pediatric" data-topicid="12725" href="/d/drug information/12725.html" rel="external">prednisone</a> remains the preferred therapy in the absence of significant steroid toxicity. Different steroid regimens have been used to treat patients with frequent relapses and/or who are steroid dependent. As noted above, in our center, we administer daily prednisone until proteinuria has resolved, which is then followed by alternate-day therapy to the patient's steroid threshold (ie, the dose at which the relapse has occurred) for 12 to 18 months.</p><p>Other regimens start with an initial <a class="drug drug_pediatric" data-topicid="12725" href="/d/drug information/12725.html" rel="external">prednisone</a> dose of 60 mg/m<sup>2</sup> per day or 2 mg/kg per day at the time of relapse but differ on the duration of treatment, including alternate-day schedule. These other regimens include:</p><p class="bulletIndent1"><span class="glyph">●</span>The 2012 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines continue <a class="drug drug_pediatric" data-topicid="12725" href="/d/drug information/12725.html" rel="external">prednisone</a> dosing of 60 mg/m<sup>2</sup> per day or 2 mg/kg per day until the urine protein tests are negative or trace for three consecutive days, followed by alternate-day prednisone for at least three months [<a href="#rid7">7</a>]. The dose of alternate-day prednisone should be the lowest dose needed to maintain remission without adverse side effects. In patients in whom alternate-day therapy is not effective in maintaining remission, the lowest possible dose of daily prednisone is given to maintain remission to minimize adverse side effects.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The Children's Nephrotic Syndrome Consensus recommends <a class="drug drug_pediatric" data-topicid="12725" href="/d/drug information/12725.html" rel="external">prednisone</a> therapy of 2 mg/kg per day (maximum of 60 mg/day) until the urine protein tests are negative or trace for three consecutive days, followed by alternate-day prednisone of 1.5 mg/kg for four weeks, which is then tapered over two months on an alternate-day schedule [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An open-label randomized controlled trial reported that daily administration of low-dose <a class="drug drug_pediatric" data-topicid="12723" href="/d/drug information/12723.html" rel="external">prednisolone</a> (0.2 to 0.3 mg/kg per day) is more effective than standard-dose alternate-day therapy (0.75 mg/kg every other day) in lowering relapse rates, sustaining remission, and enabling steroid-sparing [<a href="#rid32">32</a>].</p><p></p><p>Adrenocorticotropic hormone (ACTH) has been suggested as an alternative to corticosteroid therapy. However, in a study of patients with either frequently relapsing or steroid-dependent NS, ACTH administered twice a week at a dose of 80 international units/1.73 m<sup>2</sup> was ineffective at preventing relapses [<a href="#rid33">33</a>].</p><p>It is important to appreciate, especially when considering other therapeutic agents, that almost all frequent relapsers have a progressive decrease in the number of relapses over time and many ultimately go into permanent remission [<a href="#rid34">34</a>]. Steroid-sparing agents should be considered in children who have significant steroid toxicity. (See <a class="local">'Alternative treatments for patients with steroid toxicity'</a> below.)</p><p class="headingAnchor" id="H81224475"><span class="h3">Infections as relapse triggers</span><span class="headingEndMark"> — </span>Viral infections are a documented trigger for a relapse in children with NS [<a href="#rid35">35</a>]. In our practice, a short-term increase to daily maintenance dosing (using the same dose that was given on alternate days) is administered to patients with frequent relapsing SSNS for five to seven days during an episode of intercurrent infections. This intervention appears to reduce the risk of relapse [<a href="#rid36">36-39</a>].</p><p class="headingAnchor" id="H3189010980"><span class="h2">Late steroid resistance</span><span class="headingEndMark"> — </span>In a small number of cases, patients who were initially steroid sensitive become steroid resistant [<a href="#rid40">40-42</a>]. Although data are limited, case reports suggest that complete or partial remission can be achieved in the majority of patients using alternative immunosuppressive therapeutic agents [<a href="#rid40">40,41</a>]. However, these patients are at risk for kidney function impairment and developing end-stage kidney disease (ESKD) [<a href="#rid40">40</a>].</p><p>Based on the available evidence, we suggest that nonsteroidal therapy be offered in patients who develop late steroid resistance. In our center, we use calcineurin inhibitors (CNIs) and/or <a class="drug drug_pediatric" data-topicid="12971" href="/d/drug information/12971.html" rel="external">rituximab</a>. (See <a class="local">'Calcineurin inhibitors'</a> below.)</p><p class="headingAnchor" id="H13"><span class="h2">Alternative treatments for patients with steroid toxicity</span><span class="headingEndMark"> — </span>Complications secondary to prolonged steroid therapy are well known and are seen in children with NS, especially those with frequent relapses or steroid dependency.</p><p class="headingAnchor" id="H3642058328"><span class="h3">Indications</span><span class="headingEndMark"> — </span>Steroid-sparing immunosuppressive agents are indicated for any child with NS who displays any of the major side effects of steroids [<a href="#rid6">6-8,43</a>]. (See  <a class="medical medical_review" href="/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p>In children with NS, the most frequent signs of steroid toxicity include:</p><p class="bulletIndent1"><span class="glyph">●</span>Statural growth impairment [<a href="#rid44">44</a>]. Low-dose alternate-day therapy can preserve growth [<a href="#rid45">45</a>], and catchup growth often occurs when steroid therapy is discontinued [<a href="#rid46">46</a>]. One small observational study found that growth was not negatively impacted with doses of <a class="drug drug_pediatric" data-topicid="12723" href="/d/drug information/12723.html" rel="external">prednisolone</a> below 0.75 mg/kg per day [<a href="#rid47">47</a>]. We prefer alternate-day therapy whenever possible to preserve normal growth as much as possible.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cataracts [<a href="#rid48">48,49</a>]. (See  <a class="medical medical_review" href="/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids", section on 'Ophthalmologic effects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Excessive weight gain and cushingoid features, which can persist into adulthood [<a href="#rid50">50</a>]. (See  <a class="medical medical_review" href="/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids", section on 'Dermatologic effects and appearance'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Suppression of the hypothalamic-pituitary-adrenal axis [<a href="#rid51">51</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Behavior disturbances (hyperactivity, depression). (See  <a class="medical medical_review" href="/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids", section on 'Neuropsychiatric effects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Osteopenia. (See  <a class="medical medical_review" href="/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids", section on 'Bone and muscle effects'</a>.)</p><p></p><p class="headingAnchor" id="H2721154952"><span class="h3">Choice of agent</span><span class="headingEndMark"> — </span>In children with SSNS and evidence of steroid toxicity, the optimal steroid-sparing immunosuppressive agent should maintain long-term remission in the majority of patients, allowing for a reduction in steroid dosing and toxicity, and have no significant side effects. However, there is no clear evidence that any of the currently used immunosuppressive agents provide long-term efficacy without significant side effects [<a href="#rid43">43</a>]. These agents include levamisole, <a class="drug drug_pediatric" data-topicid="12624" href="/d/drug information/12624.html" rel="external">mycophenolate</a> mofetil (MMF), CNIs, (<a class="drug drug_pediatric" data-topicid="13193" href="/d/drug information/13193.html" rel="external">cyclosporine</a> and <a class="drug drug_pediatric" data-topicid="12822" href="/d/drug information/12822.html" rel="external">tacrolimus</a>), alkylating agents, and <a class="drug drug_pediatric" data-topicid="12971" href="/d/drug information/12971.html" rel="external">rituximab</a>.</p><p>Our approach:</p><p class="bulletIndent1"><span class="glyph">●</span>We suggest the use of levamisole, if it is available, as it has the least side effects and has shown to have a steroid-sparing effect.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>MMF is our next choice as it appears to have similar efficacy to other nonsteroidal immunosuppressive agents, but with less toxicity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients who fail to maintain remission after treatment with levamisole and/or MMF, we switch to a CNI.</p><p></p><p class="headingAnchor" id="H2740979220"><span class="h2">Steroid-sparing immunosuppressive agents</span><span class="headingEndMark"> — </span>The following discussion reviews data on specific steroid-sparing immunosuppressive agents.</p><p class="headingAnchor" id="H1001620788"><span class="h3">Levamisole</span><span class="headingEndMark"> — </span>Levamisole, which stimulates the immune system, has been shown to have a steroid-sparing effect in children with SSNS [<a href="#rid43">43,52-59</a>]. It is the least toxic and least expensive drug for preventing relapses, and if available, the initial preferred steroid-sparing medication. However, availability is limited worldwide [<a href="#rid60">60</a>] and it is not available in the United States or Canada.</p><p>In our practice, the dose of levamisole is usually 2 to 2.5 mg/kg given on alternate days (maximum dose of 150 mg), which is consistent with the recommendations from the 2012 KDIGO guidelines [<a href="#rid7">7</a>]. Regular monitoring of complete blood count should be performed because the most serious adverse effect of levamisole is reversible neutropenia. Monitoring of antineutrophil cytoplasmic autoantibody (ANCA) titers is recommended as ANCA vasculitis has been reported with cutaneous vasculitis or arthritis [<a href="#rid61">61</a>].</p><p>The following studies demonstrate the effectiveness of levamisole:</p><p class="bulletIndent1"><span class="glyph">●</span>In a multinational clinical trial of children managed with standard steroid therapy, the addition of levamisole for one year compared with placebo increased the time following termination of steroid therapy and increased the remission rate at 12 months (26 versus 6 percent) [<a href="#rid59">59</a>]. However, most patients relapsed after cessation of treatment. Reversible neutropenia was the most common adverse effect, occurring in approximately two percent of treated patients. Other reported rare severe adverse effects of levamisole (eg, hepatitis, seizures, and ANCA vasculitis) were not observed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an open-label trial of children with frequently relapsing or steroid-dependent NS, levamisole (2.5 mg/kg on alternate days) and MMF (750 to 1000 mg/m<sup>2</sup>) had similar rates of sustained remission, reduction of steroid use, and frequency of relapses [<a href="#rid62">62</a>]. The rates of adverse effects were low and also similar in both groups treated with levamisole and MMF.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A prospective study has shown that levamisole at 2.5 mg/kg daily was effective and safe. The mean number of relapses per patients was 2.8±0.8 in patients on an alternate-day schedule of levamisole and 1.3±0.9 on a daily schedule of levamisole [<a href="#rid63">63</a>].</p><p></p><p class="headingAnchor" id="H3073459340"><span class="h3">Mycophenolate mofetil</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="12624" href="/d/drug information/12624.html" rel="external">Mycophenolate</a> mofetil (MMF) inhibits T- and B-cell proliferation. Several studies suggest that MMF is effective in increasing the duration of remission in children with idiopathic NS, which may allow withdrawal of steroids or CNIs [<a href="#rid62">62,64-70</a>]. In one open-label trial, MMF was equally as effective as levamisole [<a href="#rid62">62</a>]. Data comparing MMF with CNIs (specifically <a class="drug drug_pediatric" data-topicid="13193" href="/d/drug information/13193.html" rel="external">cyclosporine</a>) are limited, but suggest that MMF is not as effective as cyclosporine in achieving remission [<a href="#rid43">43,71,72</a>]. However, MMF is not nephrotoxic and as a result, we prefer to administer MMF as the initial steroid-sparing agent when levamisole is not available, and prescribe CNIs only if the patient fails to respond to MMF.</p><p>Relapses often occur after the treatment is discontinued. It also appears that higher mycophenolic acid (MPA, the active metabolite of MMF) exposure in children with NS compared with kidney transplant recipients are needed to sustain remission [<a href="#rid73">73</a>]. As a result, therapeutic drug monitoring is recommended so that target MPA-AUC (area under the curve) exposure is maintained above 45 microg·h/mL [<a href="#rid74">74-77</a>]. This higher level does not appear to be associated with increased side effects compared with lower exposure.</p><p>Side effects of MMF include gastrointestinal disturbances (abdominal pain and diarrhea) and hematological abnormalities. Because MMF is teratogenic, use of contraception is recommended in adolescent females [<a href="#rid78">78</a>].</p><p class="headingAnchor" id="H1286775984"><span class="h3">Calcineurin inhibitors</span><span class="headingEndMark"> — </span>CNIs, such as <a class="drug drug_pediatric" data-topicid="13193" href="/d/drug information/13193.html" rel="external">cyclosporine</a> and <a class="drug drug_pediatric" data-topicid="12822" href="/d/drug information/12822.html" rel="external">tacrolimus</a>, block T-cell activation and have been used to treat patients with frequently relapsing or steroid-dependent NS. However, long-term therapy is generally required to maintain remission, which increases the risk for drug-induced nephrotoxicity [<a href="#rid79">79</a>]. In our center, we use cyclosporine for patients who do not respond to MMF.</p><p>Because of the concern for nephrotoxicity, the plasma creatinine concentration should be monitored regularly in patients who are maintained on a long-term course of CNIs. Despite ongoing monitoring of kidney function, serial kidney biopsies may demonstrate histologic lesions of nephrotoxicity without clinical evidence of kidney function impairment. Thus, we routinely perform a kidney biopsy in asymptomatic patients after 18 to 24 months of CNI therapy [<a href="#rid79">79-82</a>]. (See  <a class="medical medical_review" href="/d/html/7357.html" rel="external">"Cyclosporine and tacrolimus nephrotoxicity"</a>.)</p><p>Published data regarding the efficacy of CNIs are more robust for <a class="drug drug_pediatric" data-topicid="13193" href="/d/drug information/13193.html" rel="external">cyclosporine</a>, which was the first available CNI:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cyclosporine</strong> – Data demonstrate that <a class="drug drug_pediatric" data-topicid="13193" href="/d/drug information/13193.html" rel="external">cyclosporine</a> is effective in inducing or maintaining remission in patients with frequently relapsing or steroid-dependent NS [<a href="#rid80">80,83-88</a>]. However, most patients relapse when the drug is withdrawn, thus necessitating prolonged treatment and increasing the risk of nephrotoxicity [<a href="#rid81">81,83,89,90</a>].</p><p></p><p class="bulletIndent1">The recommended starting <a class="drug drug_pediatric" data-topicid="13193" href="/d/drug information/13193.html" rel="external">cyclosporine</a> dose is 150 mg/m<sup>2</sup> per day divided into two oral doses. The dose should be adjusted to maintain trough whole blood levels between 100 and 200 ng/mL, and the level should not exceed 200 ng/mL. To limit the risk of nephrotoxicity, once remission is achieved, we recommend decreasing the dose to &lt;5 mg/kg, if possible.</p><p></p><p class="bulletIndent1">It has been our experience that patients who relapse on <a class="drug drug_pediatric" data-topicid="13193" href="/d/drug information/13193.html" rel="external">cyclosporine</a> or after cyclosporine withdrawal often respond poorly to a second or third course of treatment. Low-dose alternate-day <a class="drug drug_pediatric" data-topicid="12725" href="/d/drug information/12725.html" rel="external">prednisone</a> in combination with cyclosporine may be a better approach in these patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tacrolimus</strong> – Limited data suggest that <a class="drug drug_pediatric" data-topicid="12822" href="/d/drug information/12822.html" rel="external">tacrolimus</a> offers no advantage over <a class="drug drug_pediatric" data-topicid="13193" href="/d/drug information/13193.html" rel="external">cyclosporine</a> on maintaining remission in children with SSNS, and it has the same risk of nephrotoxicity [<a href="#rid91">91-93</a>]. However, one advantage of tacrolimus over cyclosporine is the reduced cosmetic side effects (hypertrichosis, gum hypertrophy).</p><p></p><p class="headingAnchor" id="H81224860"><span class="h3">Alkylating agents</span><span class="headingEndMark"> — </span>Alkylating agents, such as <a class="drug drug_pediatric" data-topicid="13191" href="/d/drug information/13191.html" rel="external">cyclophosphamide</a> and <a class="drug drug_pediatric" data-topicid="13144" href="/d/drug information/13144.html" rel="external">chlorambucil</a>, can induce longer lasting remissions than <a class="drug drug_pediatric" data-topicid="12725" href="/d/drug information/12725.html" rel="external">prednisone</a> alone in patients who are frequent relapsers or steroid dependent. However, these medications, which result in depletion of immune-competent cells, have serious adverse effects. As a result, the use of alkylating agents as a steroid-sparing therapy has decreased in favor of other immunosuppressive agents with similar efficacy but less significant side effects. As a result, we <strong>do not</strong> use alkylating agents in our center to treat children with NS and steroid toxicity.</p><p>Several observational studies have shown that the use of alkylating agents compared with <a class="drug drug_pediatric" data-topicid="12725" href="/d/drug information/12725.html" rel="external">prednisone</a> alone resulted in longer sustained remission in children with frequently relapsing and/or steroid-dependent NS [<a href="#rid43">43,94-99</a>]. <a class="drug drug_pediatric" data-topicid="13191" href="/d/drug information/13191.html" rel="external">Cyclophosphamide</a> is less effective in sustaining remission in children with steroid-dependent NS compared with patients with frequent relapses [<a href="#rid100">100,101</a>]. In a systematic review of 38 studies with 1,504 children, the reported remission rates were 72 and 36 percent after two and five years in patients with frequent relapses compared with 40 and 24 percent in steroid-dependent patients [<a href="#rid102">102</a>].</p><p>Nevertheless, the following serious complications are associated with alkylating agents, which have led to their decreased use [<a href="#rid102">102,103</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Neutropenia and infection – Neutropenia is a serious adverse effect of bone marrow suppression by alkylating agents. Patients receiving these medications require monitoring of their complete blood cell counts. If the white cell count falls below 3000/mm<sup>3</sup>, the drug should be withdrawn until the count rises. Treatment also should be discontinued if infection develops. There are reported cases of significant morbidity and mortality associated with varicella and the administration of <a class="drug drug_pediatric" data-topicid="13191" href="/d/drug information/13191.html" rel="external">cyclophosphamide</a>. If varicella infection occurs, <a class="drug drug_pediatric" data-topicid="13247" href="/d/drug information/13247.html" rel="external">acyclovir</a> should be administered immediately and the alkylating agent discontinued. (See  <a class="medical medical_review" href="/d/html/6102.html" rel="external">"Complications of nephrotic syndrome in children", section on 'Viral infections'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gonadal toxicity – The development of gonadal toxicity resulting in infertility generally requires a total dose greater than 200 to 300 mg/kg for <a class="drug drug_pediatric" data-topicid="13191" href="/d/drug information/13191.html" rel="external">cyclophosphamide</a>, which exceeds the recommended cumulative dose used to treat children with NS (168 mg/kg for cyclophosphamide) [<a href="#rid104">104,105</a>]. The gonadal toxicity threshold for <a class="drug drug_pediatric" data-topicid="13144" href="/d/drug information/13144.html" rel="external">chlorambucil</a> is 8 to 10 mg/kg.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Malignancy – In a 2001 systematic review of the literature that included 1504 patients, 14 cases of malignancies were reported after high doses (greater than the above recommended standard dosing) of either <a class="drug drug_pediatric" data-topicid="13191" href="/d/drug information/13191.html" rel="external">cyclophosphamide</a> or <a class="drug drug_pediatric" data-topicid="13144" href="/d/drug information/13144.html" rel="external">chlorambucil</a> [<a href="#rid102">102</a>]. There was also a single reported case of malignancy (acute lymphoblastic leukemia) associated with cyclophosphamide administered in a child with NS using the above recommended regimen [<a href="#rid106">106</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Alopecia and hemorrhagic cystitis – These are uncommon complications that occur at the recommended doses used to treat children with NS.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Seizures – <a class="drug drug_pediatric" data-topicid="13144" href="/d/drug information/13144.html" rel="external">Chlorambucil</a> has been associated with an increased risk of seizures in children with NS [<a href="#rid107">107</a>].</p><p></p><p>If an alkylating agent is used, oral <a class="drug drug_pediatric" data-topicid="13191" href="/d/drug information/13191.html" rel="external">cyclophosphamide</a> is given at a dose of 2 mg/kg per day for 12 weeks (cumulative dose 168 mg/kg). The maximum daily dose should not exceed 2.5 mg/kg. This cumulative dose appears to minimize the most serious long-term adverse effects.</p><p class="headingAnchor" id="H20"><span class="h3">Rituximab</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="12971" href="/d/drug information/12971.html" rel="external">Rituximab</a>, a chimeric anti-CD20 monoclonal antibody that depletes B-cell lymphocytes, appears to be effective in prolonging remission in steroid-dependent or CNI-dependent patients and reducing the use of one or more immunosuppressive agents [<a href="#rid43">43</a>]. In our practice, rituximab is considered only for children with serious adverse effects from their immunosuppressive medications based on the judgement of clinicians who have expertise in the care of children with NS requiring multiple immunosuppressive agents because of concern for severe adverse effects and uncertainty regarding the optimum dosing of rituximab and long-term efficacy [<a href="#rid43">43,108</a>].</p><p>Several small trials, many of them open-label studies, have reported that administration of <a class="drug drug_pediatric" data-topicid="12971" href="/d/drug information/12971.html" rel="external">rituximab</a> alone or with corticosteroids was associated with a longer duration of remission and allowed for discontinuation or decrease in the dose of one or more immunosuppressive agents [<a href="#rid43">43,109-114</a>]. However, there is significant heterogeneity amongst these studies with variation in the patient population including differences in previous immunosuppressive treatment, dosing and frequency of rituximab therapy, and outcome measurements. As a result, the optimum dosing schedule for rituximab in children with steroid-dependent NS or frequently relapsing NS has not been established. Low versus high dose and the use of single versus multiple administrations remain areas of controversy [<a href="#rid115">115-117</a>].</p><p>A significant proportion of patients relapse after <a class="drug drug_pediatric" data-topicid="12971" href="/d/drug information/12971.html" rel="external">rituximab</a> administration with the recovery of B-cell lymphocytes [<a href="#rid118">118,119</a>]. In a randomized trial, treatment with a single dose of rituximab was superior to <a class="drug drug_pediatric" data-topicid="12822" href="/d/drug information/12822.html" rel="external">tacrolimus</a> at one year follow-up (90 versus 63 percent relapse-free survival) [<a href="#rid112">112</a>], but all participants had relapsed by two years follow-up [<a href="#rid119">119</a>]. Maintenance therapy with either MMF or <a class="drug drug_pediatric" data-topicid="13193" href="/d/drug information/13193.html" rel="external">cyclosporine</a> has been reported to reduce relapses after treatment with rituximab [<a href="#rid119">119-121</a>].</p><p>However, <a class="drug drug_pediatric" data-topicid="12971" href="/d/drug information/12971.html" rel="external">rituximab</a> is associated with severe and potentially life-threatening complications [<a href="#rid108">108</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Infusion-related reactions occur within the initial 30 to 120 minutes of the first exposure and include headache, fever, chills, sweats, skin rash, dyspnea, mild hypotension, nausea, rhinitis, pruritus, asthenia, back pain, and less commonly, bronchospasm and hypotension. Certain signs and symptoms are highly suggestive of anaphylaxis, such as urticaria, repetitive cough, wheeze, and throat tightness/change in voice. In these patients, treatment with <a class="drug drug_pediatric" data-topicid="12971" href="/d/drug information/12971.html" rel="external">rituximab</a> should be discontinued. (See  <a class="medical medical_review" href="/d/html/7501.html" rel="external">"Rituximab: Principles of use and adverse effects in rheumatoid arthritis", section on 'Infusion reactions'</a> and  <a class="medical medical_review" href="/d/html/7501.html" rel="external">"Rituximab: Principles of use and adverse effects in rheumatoid arthritis", section on 'Management of infusion reactions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Leukopenia and/or hypogammaglobulinemia resulting in serious infections, including <em>Pneumocystis</em> <em>carinii</em> pneumonia [<a href="#rid122">122,123</a>]. In one case report, a child with NS developed viral myocarditis due to enterovirus requiring cardiac transplantation [<a href="#rid124">124</a>]. (See  <a class="medical medical_review" href="/d/html/7501.html" rel="external">"Rituximab: Principles of use and adverse effects in rheumatoid arthritis", section on 'Effects on B cells, antibodies, and risk of infection'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other less common adverse effects include serious mucocutaneous reactions (Stevens-Johnson syndrome, vesiculobullous dermatitis, toxic epidermal necrolysis, and ulcerative gastrointestinal disease). There is also a published case report of death due to lung fibrosis [<a href="#rid125">125</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The development of anti-rituximab antibodies has also been reported, which may be associated with decreased efficacy and an increase in infusion reactions for subsequent repeated administration of <a class="drug drug_pediatric" data-topicid="12971" href="/d/drug information/12971.html" rel="external">rituximab</a> [<a href="#rid126">126-128</a>]. (See  <a class="medical medical_review" href="/d/html/7501.html" rel="external">"Rituximab: Principles of use and adverse effects in rheumatoid arthritis", section on 'Human antichimeric antibodies'</a>.)</p><p></p><p class="headingAnchor" id="H174702759"><span class="h2">Long-term outcome of steroid-sensitive nephrotic syndrome</span><span class="headingEndMark"> — </span>Limited data on adult long-term outcome of children with SSNS suggest that patients who had frequent relapses or steroid-dependent NS during childhood are at risk for relapses during adulthood and for drug adverse effects [<a href="#rid50">50,129-131</a>]. Kidney function remains normal in adulthood as long as the patients remain responsive to treatment [<a href="#rid129">129,130</a>] and long-term sequelae are generally related to side effects of medications.</p><p class="headingAnchor" id="H323401929"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110405.html" rel="external">"Society guideline links: Nephrotic syndrome in children"</a>.)</p><p class="headingAnchor" id="H37"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial management: Empiric steroids</strong> – In children with nephrotic syndrome (NS) who have a high probability of having minimal change disease (MCD) based on clinical and laboratory findings, we recommend empiric therapy with oral <a class="drug drug_pediatric" data-topicid="12725" href="/d/drug information/12725.html" rel="external">prednisone</a>, thus avoiding kidney biopsy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). MCD is the most common cause of NS in children, accounting for 75 to 80 percent of pediatric cases. (See <a class="local">'Empiric steroid therapy versus kidney biopsy'</a> above.)</p><p></p><p class="bulletIndent1">In our center, we start with oral <a class="drug drug_pediatric" data-topicid="12725" href="/d/drug information/12725.html" rel="external">prednisone</a> at a dose of 60 mg/m<sup>2</sup> per day (maximum of 60 mg/day). When proteinuria disappears, prednisone is continued at the same daily dose for a total of 30 days, followed by alternate-day therapy at 40 mg/m<sup>2</sup> (maximum dose 60 mg) every other day for one month. Other experts in the field also use the same initial dose of steroid, but the duration of initial therapy following onset of remission varies among pediatric nephrologists. (See <a class="local">'Initial steroid course'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Remission: Steroid-sensitive NS (SSNS)</strong> – Most children with idiopathic NS will respond to initial steroid therapy. After six months of initial steroid therapy, approximately 30 percent of children with SSNS will not relapse, 10 to 20 percent will have less than four relapses, and the remaining will have frequent relapses and/or relapse while on steroid therapy (steroid dependent). (See <a class="local">'Outcome based on response'</a> above.)</p><p></p><p class="bulletIndent1">For children with SSNS, the preferred intervention generally is steroid therapy for subsequent relapses.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>With the initial relapse or for infrequent relapses, we administer oral <a class="drug drug_pediatric" data-topicid="12725" href="/d/drug information/12725.html" rel="external">prednisone</a> at a daily dose of 60 mg/m<sup>2</sup> or 2 mg/kg (maximum of 60 mg/day) until proteinuria resolves for three days, at which point, alternative-day therapy is initiated and tapered over four weeks. Other centers use a similar approach with variation on the dosing and length of therapy. (See <a class="local">'Initial or infrequent relapse'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For children with frequently relapsing and/or steroid-dependent NS, we administer oral <a class="drug drug_pediatric" data-topicid="12725" href="/d/drug information/12725.html" rel="external">prednisone</a> at a daily dose of 40 to 60 mg/m<sup>2</sup> or 2 mg/kg (maximum of 60 mg/day) until proteinuria resolves, at which point, alternative-day therapy is initiated and tapered until the patient's threshold level and continued for 12 to 18 months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Steroid toxicity for patients with SSNS: Treatment options</strong> – For children who require steroids to maintain remission and have evidence of steroid toxicity, alternative nonsteroidal immunosuppressive agents can be added to maintain remission while reducing steroid dosing and toxicity. (See <a class="local">'Initial or infrequent relapse'</a> above and <a class="local">'Frequently relapsing/steroid-dependent nephrotic syndrome'</a> above and <a class="local">'Alternative treatments for patients with steroid toxicity'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We suggest levamisole as the initial steroid-sparing immunosuppressive agent compared with other immunosuppressive agents (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). It is the least expensive and least toxic of the effective therapeutic choices. However, levamisole has limited global availability. (See <a class="local">'Levamisole'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If levamisole is not available, we suggest <a class="drug drug_pediatric" data-topicid="12624" href="/d/drug information/12624.html" rel="external">mycophenolate</a> mofetil (MMF) as the initial therapy drug for patients with significant steroid toxicity compared with other agents (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Although perhaps not as effective as calcineurin inhibitors (CNIs), MMF is less nephrotoxic. (See <a class="local">'Choice of agent'</a> above and <a class="local">'Levamisole'</a> above and <a class="local">'Mycophenolate mofetil'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In other centers, CNIs are used as the initial steroid-sparing agent. However, sustained remission with these agents requires prolonged treatment and increases the risk of potentially irreversible nephrotoxicity. As a result, in our practice, <a class="drug drug_pediatric" data-topicid="13193" href="/d/drug information/13193.html" rel="external">cyclosporine</a> is only used in patients who fail to maintain remission after a course of MMF without a significant reduction in steroid dose. If CNIs are used, plasma creatinine concentration should be monitored regularly and a kidney biopsy should be performed even in asymptomatic patients after 18 to 24 months of therapy to screen for potential interstitial fibrosis. (See <a class="local">'Calcineurin inhibitors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Steroid-resistant NS (SRNS)</strong> – Ten to 15 percent of children will fail to respond to steroid therapy. These children with SRNS are at greatly increased risk for developing end-stage kidney disease (ESKD). Evaluation to determine the underlying etiology, including a kidney biopsy and screening for genetic disorders, should be performed as therapeutic decisions are based on the underlying cause. (See <a class="local">'Outcome based on response'</a> above and  <a class="medical medical_review" href="/d/html/16711.html" rel="external">"Steroid-resistant nephrotic syndrome in children: Etiology"</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children. J Pediatr 1981; 98:561.</a></li><li><a class="nounderline abstract_t">Trautmann A, Vivarelli M, Samuel S, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 2020; 35:1529.</a></li><li><a class="nounderline abstract_t">Veltkamp F, Rensma LR, Bouts AHM, LEARNS consortium. Incidence and Relapse of Idiopathic Nephrotic Syndrome: Meta-analysis. Pediatrics 2021; 148.</a></li><li><a class="nounderline abstract_t">Vivarelli M, Massella L, Ruggiero B, Emma F. Minimal Change Disease. Clin J Am Soc Nephrol 2017; 12:332.</a></li><li><a class="nounderline abstract_t">Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int 1978; 13:159.</a></li><li><a class="nounderline abstract_t">Gipson DS, Massengill SF, Yao L, et al. Management of childhood onset nephrotic syndrome. Pediatrics 2009; 124:747.</a></li><li><a class="nounderline abstract_t">Lombel RM, Gipson DS, Hodson EM, Kidney Disease: Improving Global Outcomes. Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO. Pediatr Nephrol 2013; 28:415.</a></li><li><a class="nounderline abstract_t">Samuel S, Bitzan M, Zappitelli M, et al. Canadian Society of Nephrology Commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis: management of nephrotic syndrome in children. Am J Kidney Dis 2014; 63:354.</a></li><li><a class="nounderline abstract_t">Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr. Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. J Am Soc Nephrol 1997; 8:769.</a></li><li><a class="nounderline abstract_t">Saadeh SA, Baracco R, Jain A, et al. Weight or body surface area dosing of steroids in nephrotic syndrome: is there an outcome difference? Pediatr Nephrol 2011; 26:2167.</a></li><li><a class="nounderline abstract_t">Tune BM, Mendoza SA. Treatment of the idiopathic nephrotic syndrome: regimens and outcomes in children and adults. J Am Soc Nephrol 1997; 8:824.</a></li><li><a class="nounderline abstract_t">Hogg RJ, Portman RJ, Milliner D, et al. Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and elimination (PARADE). Pediatrics 2000; 105:1242.</a></li><li><a class="nounderline abstract_t">Murnaghan K, Vasmant D, Bensman A. Pulse methylprednisolone therapy in severe idiopathic childhood nephrotic syndrome. Acta Paediatr Scand 1984; 73:733.</a></li><li><a class="nounderline abstract_t">Dossier C, Delbet JD, Boyer O, et al. Five-year outcome of children with idiopathic nephrotic syndrome: the NEPHROVIR population-based cohort study. Pediatr Nephrol 2019; 34:671.</a></li><li><a class="nounderline abstract_t">Schijvens AM, Teeninga N, Dorresteijn EM, et al. Steroid treatment for the first episode of childhood nephrotic syndrome: comparison of the 8 and 12 weeks regimen using an individual patient data meta-analysis. Eur J Pediatr 2021; 180:2849.</a></li><li><a class="nounderline abstract_t">Sinha A, Bagga A, Banerjee S, et al. Steroid Sensitive Nephrotic Syndrome: Revised Guidelines. Indian Pediatr 2021; 58:461.</a></li><li><a class="nounderline abstract_t">Hodson EM, Knight JF, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev 2005; :CD001533.</a></li><li><a class="nounderline abstract_t">Sinha A, Saha A, Kumar M, et al. Extending initial prednisolone treatment in a randomized control trial from 3 to 6 months did not significantly influence the course of illness in children with steroid-sensitive nephrotic syndrome. Kidney Int 2015; 87:217.</a></li><li><a class="nounderline abstract_t">Yoshikawa N, Nakanishi K, Sako M, et al. A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment. Kidney Int 2015; 87:225.</a></li><li><a class="nounderline abstract_t">Webb NJA, Woolley RL, Lambe T, et al. Long term tapering versus standard prednisolone treatment for first episode of childhood nephrotic syndrome: phase III randomised controlled trial and economic evaluation. BMJ 2019; 365:l1800.</a></li><li><a class="nounderline abstract_t">Hodson EM, Hahn D, Craig JC. Corticosteroids for the initial episode of steroid-sensitive nephrotic syndrome. Pediatr Nephrol 2015; 30:1043.</a></li><li><a class="nounderline abstract_t">Larkins N, Kim S, Craig J, Hodson E. Steroid-sensitive nephrotic syndrome: an evidence-based update of immunosuppressive treatment in children. Arch Dis Child 2016; 101:404.</a></li><li><a class="nounderline abstract_t">Leisti S, Koskimies O. Risk of relapse in steroid-sensitive nephrotic syndrome: effect of stage of post-prednisone adrenocortical suppression. J Pediatr 1983; 103:553.</a></li><li><a class="nounderline abstract_t">Leonard MB, Feldman HI, Shults J, et al. Long-term, high-dose glucocorticoids and bone mineral content in childhood glucocorticoid-sensitive nephrotic syndrome. N Engl J Med 2004; 351:868.</a></li><li><a class="nounderline abstract_t">Hoyer PF, Brodeh J. Initial treatment of idiopathic nephrotic syndrome in children: prednisone versus prednisone plus cyclosporine A: a prospective, randomized trial. J Am Soc Nephrol 2006; 17:1151.</a></li><li><a class="nounderline abstract_t">Carter SA, Mistry S, Fitzpatrick J, et al. Prediction of Short- and Long-Term Outcomes in Childhood Nephrotic Syndrome. Kidney Int Rep 2020; 5:426.</a></li><li><a class="nounderline abstract_t">Hodson EM, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev 2007; :CD001533.</a></li><li><a class="nounderline abstract_t">Kainth D, Hari P, Sinha A, et al. Short-Duration Prednisolone in Children with Nephrotic Syndrome Relapse: A Noninferiority Randomized Controlled Trial. Clin J Am Soc Nephrol 2021; 16:225.</a></li><li><a class="nounderline abstract_t">Gargiulo A, Massella L, Ruggiero B, et al. Results of the PROPINE randomized controlled study suggest tapering of prednisone treatment for relapses of steroid sensitive nephrotic syndrome is not necessary in children. Kidney Int 2021; 99:475.</a></li><li class="breakAll">Broyer M, Meyrier A, Niaudet P, Habib R. Minimal changes and focal and segmental glomerular sclerosis. In: Oxford Textbook of Clinical Nephrology, Cameron JS, Davison MA, Grünfeld JP, et al (Eds), Oxford Medical Publications, 1992. p.298.</li><li><a class="nounderline abstract_t">Kemper MJ, Valentin L, van Husen M. Difficult-to-treat idiopathic nephrotic syndrome: established drugs, open questions and future options. Pediatr Nephrol 2018; 33:1641.</a></li><li><a class="nounderline abstract_t">Yadav M, Sinha A, Khandelwal P, et al. Efficacy of low-dose daily versus alternate-day prednisolone in frequently relapsing nephrotic syndrome: an open-label randomized controlled trial. Pediatr Nephrol 2019; 34:829.</a></li><li><a class="nounderline abstract_t">Wang CS, Travers C, McCracken C, et al. Adrenocorticotropic Hormone for Childhood Nephrotic Syndrome: The ATLANTIS Randomized Trial. Clin J Am Soc Nephrol 2018; 13:1859.</a></li><li><a class="nounderline abstract_t">Welch TR, Gianis J, Sheldon CA. Perforation of the scrotum complicating nephrotic syndrome. J Pediatr 1988; 113:336.</a></li><li><a class="nounderline abstract_t">MacDonald NE, Wolfish N, McLaine P, et al. Role of respiratory viruses in exacerbations of primary nephrotic syndrome. J Pediatr 1986; 108:378.</a></li><li><a class="nounderline abstract_t">Mattoo TK, Mahmoud MA. Increased maintenance corticosteroids during upper respiratory infection decrease the risk of relapse in nephrotic syndrome. Nephron 2000; 85:343.</a></li><li><a class="nounderline abstract_t">Abeyagunawardena AS, Trompeter RS. Increasing the dose of prednisolone during viral infections reduces the risk of relapse in nephrotic syndrome: a randomised controlled trial. Arch Dis Child 2008; 93:226.</a></li><li><a class="nounderline abstract_t">Gulati A, Sinha A, Sreenivas V, et al. Daily corticosteroids reduce infection-associated relapses in frequently relapsing nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol 2011; 6:63.</a></li><li><a class="nounderline abstract_t">Abeyagunawardena AS, Thalgahagoda RS, Dissanayake PV, et al. Short courses of daily prednisolone during upper respiratory tract infections reduce relapse frequency in childhood nephrotic syndrome. Pediatr Nephrol 2017; 32:1377.</a></li><li><a class="nounderline abstract_t">Straatmann C, Ayoob R, Gbadegesin R, et al. Treatment outcome of late steroid-resistant nephrotic syndrome: a study by the Midwest Pediatric Nephrology Consortium. Pediatr Nephrol 2013; 28:1235.</a></li><li><a class="nounderline abstract_t">Srivastava RN, Agarwal RK, Moudgil A, Bhuyan UN. Late resistance to corticosteroids in nephrotic syndrome. J Pediatr 1986; 108:66.</a></li><li><a class="nounderline abstract_t">Kim JS, Bellew CA, Silverstein DM, et al. High incidence of initial and late steroid resistance in childhood nephrotic syndrome. Kidney Int 2005; 68:1275.</a></li><li><a class="nounderline abstract_t">Larkins NG, Liu ID, Willis NS, et al. Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children. Cochrane Database Syst Rev 2020; 4:CD002290.</a></li><li><a class="nounderline abstract_t">Hyams JS, Carey DE. Corticosteroids and growth. J Pediatr 1988; 113:249.</a></li><li><a class="nounderline abstract_t">Polito C, Oporto MR, Totino SF, et al. Normal growth of nephrotic children during long-term alternate-day prednisone therapy. Acta Paediatr Scand 1986; 75:245.</a></li><li><a class="nounderline abstract_t">FLEISHER DS, McCRORY WW, RAPOPORT M. The effects of intermittent doses of adrenocortical steroids on the statural growth of nephrotic children. J Pediatr 1960; 57:192.</a></li><li><a class="nounderline abstract_t">Simmonds J, Grundy N, Trompeter R, Tullus K. Long-term steroid treatment and growth: a study in steroid-dependent nephrotic syndrome. Arch Dis Child 2010; 95:146.</a></li><li><a class="nounderline abstract_t">Brocklebank JT, Harcourt RB, Meadow SR. Corticosteroid-induced cataracts in idiopathic nephrotic syndrome. Arch Dis Child 1982; 57:30.</a></li><li><a class="nounderline abstract_t">Ng JS, Wong W, Law RW, et al. Ocular complications of paediatric patients with nephrotic syndrome. Clin Exp Ophthalmol 2001; 29:239.</a></li><li><a class="nounderline abstract_t">Fakhouri F, Bocquet N, Taupin P, et al. Steroid-sensitive nephrotic syndrome: from childhood to adulthood. Am J Kidney Dis 2003; 41:550.</a></li><li><a class="nounderline abstract_t">Abeyagunawardena AS, Hindmarsh P, Trompeter RS. Adrenocortical suppression increases the risk of relapse in nephrotic syndrome. Arch Dis Child 2007; 92:585.</a></li><li><a class="nounderline abstract_t">Mongeau JG, Robitaille PO, Roy F. Clinical efficacy of levamisole in the treatment of primary nephrosis in children. Pediatr Nephrol 1988; 2:398.</a></li><li><a class="nounderline abstract_t">Alsaran K, Grisaru S, Stephens D, Arbus G. Levamisole vs. cyclophosphamide for frequently-relapsing steroid-dependent nephrotic syndrome. Clin Nephrol 2001; 56:289.</a></li><li><a class="nounderline abstract_t">Barletta GM, Smoyer WE, Bunchman TE, et al. Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome. Pediatr Nephrol 2003; 18:833.</a></li><li><a class="nounderline abstract_t">Levamisole for corticosteroid-dependent nephrotic syndrome in childhood. British Association for Paediatric Nephrology. Lancet 1991; 337:1555.</a></li><li><a class="nounderline abstract_t">Boyer O, Moulder JK, Grandin L, Somers MJ. Short- and long-term efficacy of levamisole as adjunctive therapy in childhood nephrotic syndrome. Pediatr Nephrol 2008; 23:575.</a></li><li><a class="nounderline abstract_t">Sümegi V, Haszon I, Iványi B, et al. Long-term effects of levamisole treatment in childhood nephrotic syndrome. Pediatr Nephrol 2004; 19:1354.</a></li><li><a class="nounderline abstract_t">Elmas AT, Tabel Y, Elmas ON. Short- and long-term efficacy of levamisole in children with steroid-sensitive nephrotic syndrome. Int Urol Nephrol 2013; 45:1047.</a></li><li><a class="nounderline abstract_t">Gruppen MP, Bouts AH, Jansen-van der Weide MC, et al. A randomized clinical trial indicates that levamisole increases the time to relapse in children with steroid-sensitive idiopathic nephrotic syndrome. Kidney Int 2018; 93:510.</a></li><li><a class="nounderline abstract_t">Davin JC, Merkus MP. Levamisole in steroid-sensitive nephrotic syndrome of childhood: the lost paradise? Pediatr Nephrol 2005; 20:10.</a></li><li><a class="nounderline abstract_t">Vivarelli M, Emma F. Levamisole for children with nephrotic syndrome: new evidence for the use of an "old" drug. Kidney Int 2019; 95:25.</a></li><li><a class="nounderline abstract_t">Sinha A, Puraswani M, Kalaivani M, et al. Efficacy and safety of mycophenolate mofetil versus levamisole in frequently relapsing nephrotic syndrome: an open-label randomized controlled trial. Kidney Int 2019; 95:210.</a></li><li><a class="nounderline abstract_t">Abeyagunawardena AS, Karunadasa U, Jayaweera H, et al. Efficacy of higher-dose levamisole in maintaining remission in steroid-dependant nephrotic syndrome. Pediatr Nephrol 2017; 32:1363.</a></li><li><a class="nounderline abstract_t">Bagga A, Hari P, Moudgil A, Jordan SC. Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome. Am J Kidney Dis 2003; 42:1114.</a></li><li><a class="nounderline abstract_t">Novak I, Frank R, Vento S, et al. Efficacy of mycophenolate mofetil in pediatric patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol 2005; 20:1265.</a></li><li><a class="nounderline abstract_t">Hogg RJ, Fitzgibbons L, Bruick J, et al. Mycophenolate mofetil in children with frequently relapsing nephrotic syndrome: a report from the Southwest Pediatric Nephrology Study Group. Clin J Am Soc Nephrol 2006; 1:1173.</a></li><li><a class="nounderline abstract_t">Fujinaga S, Ohtomo Y, Umino D, et al. A prospective study on the use of mycophenolate mofetil in children with cyclosporine-dependent nephrotic syndrome. Pediatr Nephrol 2007; 22:71.</a></li><li><a class="nounderline abstract_t">Afzal K, Bagga A, Menon S, et al. Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome. Pediatr Nephrol 2007; 22:2059.</a></li><li><a class="nounderline abstract_t">Banerjee S, Pahari A, Sengupta J, Patnaik SK. Outcome of severe steroid-dependent nephrotic syndrome treated with mycophenolate mofetil. Pediatr Nephrol 2013; 28:93.</a></li><li><a class="nounderline abstract_t">Dehoux L, Hogan J, Dossier C, et al. Mycophenolate mofetil in steroid-dependent idiopathic nephrotic syndrome. Pediatr Nephrol 2016; 31:2095.</a></li><li><a class="nounderline abstract_t">Dorresteijn EM, Kist-van Holthe JE, Levtchenko EN, et al. Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome. Pediatr Nephrol 2008; 23:2013.</a></li><li><a class="nounderline abstract_t">Gellermann J, Weber L, Pape L, et al. Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome. J Am Soc Nephrol 2013; 24:1689.</a></li><li><a class="nounderline abstract_t">Querfeld U, Weber LT. Mycophenolate mofetil for sustained remission in nephrotic syndrome. Pediatr Nephrol 2018; 33:2253.</a></li><li><a class="nounderline abstract_t">Sobiak J, Resztak M, Ostalska-Nowicka D, et al. Monitoring of mycophenolate mofetil metabolites in children with nephrotic syndrome and the proposed novel target values of pharmacokinetic parameters. Eur J Pharm Sci 2015; 77:189.</a></li><li><a class="nounderline abstract_t">Tong K, Mao J, Fu H, et al. The Value of Monitoring the Serum Concentration of Mycophenolate Mofetil in Children with Steroid-Dependent/Frequent Relapsing Nephrotic Syndrome. Nephron 2016; 132:327.</a></li><li><a class="nounderline abstract_t">Hackl Á, Cseprekál O, Gessner M, et al. Mycophenolate Mofetil Therapy in Children With Idiopathic Nephrotic Syndrome: Does Therapeutic Drug Monitoring Make a Difference? Ther Drug Monit 2016; 38:274.</a></li><li><a class="nounderline abstract_t">Tellier S, Dallocchio A, Guigonis V, et al. Mycophenolic Acid Pharmacokinetics and Relapse in Children with Steroid-Dependent Idiopathic Nephrotic Syndrome. Clin J Am Soc Nephrol 2016; 11:1777.</a></li><li><a class="nounderline abstract_t">Perez-Aytes A, Ledo A, Boso V, et al. In utero exposure to mycophenolate mofetil: a characteristic phenotype? Am J Med Genet A 2008; 146A:1.</a></li><li><a class="nounderline abstract_t">Delbet JD, Aoun B, Buob D, et al. Infrequent tacrolimus-induced nephrotoxicity in French patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol 2019; 34:2605.</a></li><li><a class="nounderline abstract_t">Habib R, Niaudet P. Comparison between pre- and posttreatment renal biopsies in children receiving ciclosporine for idiopathic nephrosis. Clin Nephrol 1994; 42:141.</a></li><li><a class="nounderline abstract_t">Kengne-Wafo S, Massella L, Diomedi-Camassei F, et al. Risk factors for cyclosporin A nephrotoxicity in children with steroid-dependant nephrotic syndrome. Clin J Am Soc Nephrol 2009; 4:1409.</a></li><li><a class="nounderline abstract_t">Hamasaki Y, Komaki F, Ishikura K, et al. Nephrotoxicity in children with frequently relapsing nephrotic syndrome receiving long-term cyclosporine treatment. Pediatr Nephrol 2017; 32:1383.</a></li><li><a class="nounderline abstract_t">Niaudet P, Habib R. Cyclosporine in the treatment of idiopathic nephrosis. J Am Soc Nephrol 1994; 5:1049.</a></li><li><a class="nounderline abstract_t">Niaudet P, Broyer M, Habib R. Treatment of idiopathic nephrotic syndrome with cyclosporin A in children. Clin Nephrol 1991; 35 Suppl 1:S31.</a></li><li><a class="nounderline abstract_t">Tejani AT, Butt K, Trachtman H, et al. Cyclosporine A induced remission of relapsing nephrotic syndrome in children. Kidney Int 1988; 33:729.</a></li><li><a class="nounderline abstract_t">Kano K, Kyo K, Yamada Y, et al. Comparison between pre- and posttreatment clinical and renal biopsies in children receiving low dose ciclosporine-A for 2 years for steroid-dependent nephrotic syndrome. Clin Nephrol 1999; 52:19.</a></li><li><a class="nounderline abstract_t">Mahmoud I, Basuni F, Sabry A, et al. Single-centre experience with cyclosporin in 106 children with idiopathic focal segmental glomerulosclerosis. Nephrol Dial Transplant 2005; 20:735.</a></li><li><a class="nounderline abstract_t">Ishikura K, Ikeda M, Hattori S, et al. Effective and safe treatment with cyclosporine in nephrotic children: a prospective, randomized multicenter trial. Kidney Int 2008; 73:1167.</a></li><li><a class="nounderline abstract_t">Ishikura K, Yoshikawa N, Nakazato H, et al. Two-year follow-up of a prospective clinical trial of cyclosporine for frequently relapsing nephrotic syndrome in children. Clin J Am Soc Nephrol 2012; 7:1576.</a></li><li><a class="nounderline abstract_t">Ishikura K, Yoshikawa N, Nakazato H, et al. Morbidity in children with frequently relapsing nephrosis: 10-year follow-up of a randomized controlled trial. Pediatr Nephrol 2015; 30:459.</a></li><li><a class="nounderline abstract_t">Dötsch J, Dittrich K, Plank C, Rascher W. Is tacrolimus for childhood steroid-dependent nephrotic syndrome better than ciclosporin A? Nephrol Dial Transplant 2006; 21:1761.</a></li><li><a class="nounderline abstract_t">Sinha MD, MacLeod R, Rigby E, Clark AG. Treatment of severe steroid-dependent nephrotic syndrome (SDNS) in children with tacrolimus. Nephrol Dial Transplant 2006; 21:1848.</a></li><li><a class="nounderline abstract_t">Wang W, Xia Y, Mao J, et al. Treatment of tacrolimus or cyclosporine A in children with idiopathic nephrotic syndrome. Pediatr Nephrol 2012; 27:2073.</a></li><li><a class="nounderline abstract_t">Cameron JS, Chantler C, Ogg CS, White RH. Long-term stability of remission in nephrotic syndrome after treatment with cyclophosphamide. Br Med J 1974; 4:7.</a></li><li><a class="nounderline abstract_t">Chiu J, Drummond KN. Long-term follow-up of cyclophosphamide therapy in frequent relapsing minimal lesion nephrotic syndrome. J Pediatr 1974; 84:825.</a></li><li><a class="nounderline abstract_t">McDonald J, Murphy AV, Arneil GC. Long-term assessment of cyclophosphamide therapy for nephrosis in children. Lancet 1974; 2:980.</a></li><li><a class="nounderline abstract_t">Vester U, Kranz B, Zimmermann S, Hoyer PF. Cyclophosphamide in steroid-sensitive nephrotic syndrome: outcome and outlook. Pediatr Nephrol 2003; 18:661.</a></li><li><a class="nounderline abstract_t">Azib S, Macher MA, Kwon T, et al. Cyclophosphamide in steroid-dependent nephrotic syndrome. Pediatr Nephrol 2011; 26:927.</a></li><li><a class="nounderline abstract_t">Cammas B, Harambat J, Bertholet-Thomas A, et al. Long-term effects of cyclophosphamide therapy in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. Nephrol Dial Transplant 2011; 26:178.</a></li><li><a class="nounderline abstract_t">Arbeitsgemeinschaft für Pädiatrische Nephrologie. Effect of cytotoxic drugs in frequently relapsing nephrotic syndrome with and without steroid dependence. N Engl J Med 1982; 306:451.</a></li><li><a class="nounderline abstract_t">Srivastava RN, Agarwal RK, Choudhry VP, et al. Cyclophosphamide therapy in frequently relapsing nephrotic syndrome with and without steroid dependence. Int J Pediatr Nephrol 1985; 6:245.</a></li><li><a class="nounderline abstract_t">Latta K, von Schnakenburg C, Ehrich JH. A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children. Pediatr Nephrol 2001; 16:271.</a></li><li><a class="nounderline abstract_t">Trompeter RS. Immunosuppressive therapy in the nephrotic syndrome in children. Pediatr Nephrol 1989; 3:194.</a></li><li><a class="nounderline abstract_t">Guesry P, Lenoir G, Broyer M. Gonadal effects of chlorambucil given to prepubertal and pubertal boys for nephrotic syndrome. J Pediatr 1978; 92:299.</a></li><li><a class="nounderline abstract_t">Watson AR, Rance CP, Bain J. Long term effects of cyclophosphamide on testicular function. Br Med J (Clin Res Ed) 1985; 291:1457.</a></li><li><a class="nounderline abstract_t">Müller W, Brandis M. Acute leukemia after cytotoxic treatment for nonmalignant disease in childhood. A case report and review of the literature. Eur J Pediatr 1981; 136:105.</a></li><li><a class="nounderline abstract_t">Williams SA, Makker SP, Grupe WE. Seizures: a significant side effect of chlorambucil therapy in children. J Pediatr 1978; 93:516.</a></li><li><a class="nounderline abstract_t">Hodson EM, Craig JC. Rituximab for childhood-onset nephrotic syndrome. Lancet 2014.</a></li><li><a class="nounderline abstract_t">Iijima K, Sako M, Nozu K, et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2014; 384:1273.</a></li><li><a class="nounderline abstract_t">Ravani P, Rossi R, Bonanni A, et al. Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial. J Am Soc Nephrol 2015; 26:2259.</a></li><li><a class="nounderline abstract_t">Kamei K, Ishikura K, Sako M, et al. Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab. Pediatr Nephrol 2017; 32:2071.</a></li><li><a class="nounderline abstract_t">Basu B, Sander A, Roy B, et al. Efficacy of Rituximab vs Tacrolimus in Pediatric Corticosteroid-Dependent Nephrotic Syndrome: A Randomized Clinical Trial. JAMA Pediatr 2018; 172:757.</a></li><li><a class="nounderline abstract_t">Ahn YH, Kim SH, Han KH, et al. Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: A multicenter open-label trial in Korea. Medicine (Baltimore) 2018; 97:e13157.</a></li><li><a class="nounderline abstract_t">Ravani P, Lugani F, Pisani I, et al. Rituximab for very low dose steroid-dependent nephrotic syndrome in children: a randomized controlled study. Pediatr Nephrol 2020; 35:1437.</a></li><li><a class="nounderline abstract_t">Maxted AP, Dalrymple RA, Chisholm D, et al. Low-dose rituximab is no less effective for nephrotic syndrome measured by 12-month outcome. Pediatr Nephrol 2019; 34:855.</a></li><li><a class="nounderline abstract_t">Hogan J, Dossier C, Kwon T, et al. Effect of different rituximab regimens on B cell depletion and time to relapse in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol 2019; 34:253.</a></li><li><a class="nounderline abstract_t">Kallash M, Smoyer WE, Mahan JD. Rituximab Use in the Management of Childhood Nephrotic Syndrome. Front Pediatr 2019; 7:178.</a></li><li><a class="nounderline abstract_t">Kamei K, Ito S, Nozu K, et al. Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol 2009; 24:1321.</a></li><li><a class="nounderline abstract_t">Basu B, Erdmann S, Sander A, et al. Long-Term Efficacy and Safety of Rituximab Versus Tacrolimus in Children With Steroid Dependent Nephrotic Syndrome. Kidney Int Rep 2023; 8:1575.</a></li><li><a class="nounderline abstract_t">Ito S, Kamei K, Ogura M, et al. Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol 2011; 26:1823.</a></li><li><a class="nounderline abstract_t">Fujinaga S, Someya T, Watanabe T, et al. Cyclosporine versus mycophenolate mofetil for maintenance of remission of steroid-dependent nephrotic syndrome after a single infusion of rituximab. Eur J Pediatr 2013; 172:513.</a></li><li><a class="nounderline abstract_t">Kamei K, Takahashi M, Fuyama M, et al. Rituximab-associated agranulocytosis in children with refractory idiopathic nephrotic syndrome: case series and review of literature. Nephrol Dial Transplant 2015; 30:91.</a></li><li><a class="nounderline abstract_t">Parmentier C, Delbet JD, Decramer S, et al. Immunoglobulin serum levels in rituximab-treated patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol 2020; 35:455.</a></li><li><a class="nounderline abstract_t">Sellier-Leclerc AL, Belli E, Guérin V, et al. Fulminant viral myocarditis after rituximab therapy in pediatric nephrotic syndrome. Pediatr Nephrol 2013; 28:1875.</a></li><li><a class="nounderline abstract_t">Chaumais MC, Garnier A, Chalard F, et al. Fatal pulmonary fibrosis after rituximab administration. Pediatr Nephrol 2009; 24:1753.</a></li><li><a class="nounderline abstract_t">Ahn YH, Kang HG, Lee JM, et al. Development of antirituximab antibodies in children with nephrotic syndrome. Pediatr Nephrol 2014; 29:1461.</a></li><li><a class="nounderline abstract_t">Fujinaga S, Nishino T, Endo S, et al. Unfavorable impact of anti-rituximab antibodies on clinical outcomes in children with complicated steroid-dependent nephrotic syndrome. Pediatr Nephrol 2020; 35:2003.</a></li><li><a class="nounderline abstract_t">Bertrand Q, Mignot S, Kwon T, et al. Anti-rituximab antibodies in pediatric steroid-dependent nephrotic syndrome. Pediatr Nephrol 2022; 37:357.</a></li><li><a class="nounderline abstract_t">Rüth EM, Kemper MJ, Leumann EP, et al. Children with steroid-sensitive nephrotic syndrome come of age: long-term outcome. J Pediatr 2005; 147:202.</a></li><li><a class="nounderline abstract_t">Kyrieleis HA, Löwik MM, Pronk I, et al. Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children. Clin J Am Soc Nephrol 2009; 4:1593.</a></li><li><a class="nounderline abstract_t">Korsgaard T, Andersen RF, Joshi S, et al. Childhood onset steroid-sensitive nephrotic syndrome continues into adulthood. Pediatr Nephrol 2019; 34:641.</a></li></ol></div><div id="topicVersionRevision">Topic 6130 Version 70.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7205481" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32382828" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34193618" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Incidence and Relapse of Idiopathic Nephrotic Syndrome: Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27940460" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Minimal Change Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/713276" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19651590" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Management of childhood onset nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23052651" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24423782" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Canadian Society of Nephrology Commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis: management of nephrotic syndrome in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9176846" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21769641" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Weight or body surface area dosing of steroids in nephrotic syndrome: is there an outcome difference?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9176855" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Treatment of the idiopathic nephrotic syndrome: regimens and outcomes in children and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10835064" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and elimination (PARADE).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6524363" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pulse methylprednisolone therapy in severe idiopathic childhood nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30552564" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Five-year outcome of children with idiopathic nephrotic syndrome: the NEPHROVIR population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33774744" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Steroid treatment for the first episode of childhood nephrotic syndrome: comparison of the 8 and 12 weeks regimen using an individual patient data meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33742610" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Steroid Sensitive Nephrotic Syndrome: Revised Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15674881" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Corticosteroid therapy for nephrotic syndrome in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25029428" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Extending initial prednisolone treatment in a randomized control trial from 3 to 6 months did not significantly influence the course of illness in children with steroid-sensitive nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25054775" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31335316" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Long term tapering versus standard prednisolone treatment for first episode of childhood nephrotic syndrome: phase III randomised controlled trial and economic evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25912994" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Corticosteroids for the initial episode of steroid-sensitive nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26289063" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Steroid-sensitive nephrotic syndrome: an evidence-based update of immunosuppressive treatment in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6312005" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Risk of relapse in steroid-sensitive nephrotic syndrome: effect of stage of post-prednisone adrenocortical suppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15329424" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Long-term, high-dose glucocorticoids and bone mineral content in childhood glucocorticoid-sensitive nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16540560" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Initial treatment of idiopathic nephrotic syndrome in children: prednisone versus prednisone plus cyclosporine A: a prospective, randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32280840" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Prediction of Short- and Long-Term Outcomes in Childhood Nephrotic Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17943754" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Corticosteroid therapy for nephrotic syndrome in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33478976" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Short-Duration Prednisolone in Children with Nephrotic Syndrome Relapse: A Noninferiority Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33152448" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Results of the PROPINE randomized controlled study suggest tapering of prednisone treatment for relapses of steroid sensitive nephrotic syndrome is not necessary in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33152448" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Results of the PROPINE randomized controlled study suggest tapering of prednisone treatment for relapses of steroid sensitive nephrotic syndrome is not necessary in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28879428" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Difficult-to-treat idiopathic nephrotic syndrome: established drugs, open questions and future options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30194663" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Efficacy of low-dose daily versus alternate-day prednisolone in frequently relapsing nephrotic syndrome: an open-label randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30442868" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Adrenocorticotropic Hormone for Childhood Nephrotic Syndrome: The ATLANTIS Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3397797" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Perforation of the scrotum complicating nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3005537" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Role of respiratory viruses in exacerbations of primary nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10940745" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Increased maintenance corticosteroids during upper respiratory infection decrease the risk of relapse in nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17573408" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Increasing the dose of prednisolone during viral infections reduces the risk of relapse in nephrotic syndrome: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20847092" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Daily corticosteroids reduce infection-associated relapses in frequently relapsing nephrotic syndrome: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28341877" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Short courses of daily prednisolone during upper respiratory tract infections reduce relapse frequency in childhood nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23633037" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Treatment outcome of late steroid-resistant nephrotic syndrome: a study by the Midwest Pediatric Nephrology Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3944696" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Late resistance to corticosteroids in nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16105061" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : High incidence of initial and late steroid resistance in childhood nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32297308" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3294360" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Corticosteroids and growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3962658" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Normal growth of nephrotic children during long-term alternate-day prednisone therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13855789" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The effects of intermittent doses of adrenocortical steroids on the statural growth of nephrotic children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20172895" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Long-term steroid treatment and growth: a study in steroid-dependent nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7065690" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Corticosteroid-induced cataracts in idiopathic nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11545423" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Ocular complications of paediatric patients with nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12612977" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Steroid-sensitive nephrotic syndrome: from childhood to adulthood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17284479" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Adrenocortical suppression increases the risk of relapse in nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3153050" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Clinical efficacy of levamisole in the treatment of primary nephrosis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11680658" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Levamisole vs. cyclophosphamide for frequently-relapsing steroid-dependent nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12774223" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1675705" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Levamisole for corticosteroid-dependent nephrotic syndrome in childhood. British Association for Paediatric Nephrology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18204939" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Short- and long-term efficacy of levamisole as adjunctive therapy in childhood nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15517419" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Long-term effects of levamisole treatment in childhood nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22826143" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Short- and long-term efficacy of levamisole in children with steroid-sensitive nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29054532" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A randomized clinical trial indicates that levamisole increases the time to relapse in children with steroid-sensitive idiopathic nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15378419" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Levamisole in steroid-sensitive nephrotic syndrome of childhood: the lost paradise?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30606425" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Levamisole for children with nephrotic syndrome: new evidence for the use of an "old" drug.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30497684" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Efficacy and safety of mycophenolate mofetil versus levamisole in frequently relapsing nephrotic syndrome: an open-label randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28299461" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Efficacy of higher-dose levamisole in maintaining remission in steroid-dependant nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14655181" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15942779" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Efficacy of mycophenolate mofetil in pediatric patients with steroid-dependent nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17699344" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Mycophenolate mofetil in children with frequently relapsing nephrotic syndrome: a report from the Southwest Pediatric Nephrology Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17086405" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : A prospective study on the use of mycophenolate mofetil in children with cyclosporine-dependent nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17938973" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22890513" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Outcome of severe steroid-dependent nephrotic syndrome treated with mycophenolate mofetil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27263020" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Mycophenolate mofetil in steroid-dependent idiopathic nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18622632" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23813218" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29750317" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Mycophenolate mofetil for sustained remission in nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26102431" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Monitoring of mycophenolate mofetil metabolites in children with nephrotic syndrome and the proposed novel target values of pharmacokinetic parameters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26991496" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : The Value of Monitoring the Serum Concentration of Mycophenolate Mofetil in Children with Steroid-Dependent/Frequent Relapsing Nephrotic Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26488204" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Mycophenolate Mofetil Therapy in Children With Idiopathic Nephrotic Syndrome: Does Therapeutic Drug Monitoring Make a Difference?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27445161" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Mycophenolic Acid Pharmacokinetics and Relapse in Children with Steroid-Dependent Idiopathic Nephrotic Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18074358" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : In utero exposure to mycophenolate mofetil: a characteristic phenotype?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31515630" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Infrequent tacrolimus-induced nephrotoxicity in French patients with steroid-dependent nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7994931" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Comparison between pre- and posttreatment renal biopsies in children receiving ciclosporine for idiopathic nephrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19628686" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Risk factors for cyclosporin A nephrotoxicity in children with steroid-dependant nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28378029" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Nephrotoxicity in children with frequently relapsing nephrotic syndrome receiving long-term cyclosporine treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7849244" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Cyclosporine in the treatment of idiopathic nephrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1860265" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Treatment of idiopathic nephrotic syndrome with cyclosporin A in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2966873" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Cyclosporine A induced remission of relapsing nephrotic syndrome in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10442491" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Comparison between pre- and posttreatment clinical and renal biopsies in children receiving low dose ciclosporine-A for 2 years for steroid-dependent nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15772265" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Single-centre experience with cyclosporin in 106 children with idiopathic focal segmental glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18305467" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Effective and safe treatment with cyclosporine in nephrotic children: a prospective, randomized multicenter trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22837276" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Two-year follow-up of a prospective clinical trial of cyclosporine for frequently relapsing nephrotic syndrome in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25277597" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Morbidity in children with frequently relapsing nephrosis: 10-year follow-up of a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16702202" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Is tacrolimus for childhood steroid-dependent nephrotic syndrome better than ciclosporin A?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16311257" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Treatment of severe steroid-dependent nephrotic syndrome (SDNS) in children with tacrolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22714672" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Treatment of tacrolimus or cyclosporine A in children with idiopathic nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4425844" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Long-term stability of remission in nephrotic syndrome after treatment with cyclophosphamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4855503" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Long-term follow-up of cyclophosphamide therapy in frequent relapsing minimal lesion nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4138088" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Long-term assessment of cyclophosphamide therapy for nephrosis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12750975" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Cyclophosphamide in steroid-sensitive nephrotic syndrome: outcome and outlook.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21394465" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Cyclophosphamide in steroid-dependent nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20610527" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Long-term effects of cyclophosphamide therapy in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7035953" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Effect of cytotoxic drugs in frequently relapsing nephrotic syndrome with and without steroid dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4093243" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Cyclophosphamide therapy in frequently relapsing nephrotic syndrome with and without steroid dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11322378" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2701868" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Immunosuppressive therapy in the nephrotic syndrome in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/621613" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Gonadal effects of chlorambucil given to prepubertal and pubertal boys for nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3933709" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Long term effects of cyclophosphamide on testicular function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6938373" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Acute leukemia after cytotoxic treatment for nonmalignant disease in childhood. A case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/690782" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Seizures: a significant side effect of chlorambucil therapy in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Rituximab for childhood-onset nephrotic syndrome</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24965823" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25592855" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28664242" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29913001" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Efficacy of Rituximab vs Tacrolimus in Pediatric Corticosteroid-Dependent Nephrotic Syndrome: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30431588" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: A multicenter open-label trial in Korea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32232637" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Rituximab for very low dose steroid-dependent nephrotic syndrome in children: a randomized controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30564878" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Low-dose rituximab is no less effective for nephrotic syndrome measured by 12-month outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30109447" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Effect of different rituximab regimens on B cell depletion and time to relapse in children with steroid-dependent nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31134169" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Rituximab Use in the Management of Childhood Nephrotic Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19421786" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37547526" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Long-Term Efficacy and Safety of Rituximab Versus Tacrolimus in Children With Steroid Dependent Nephrotic Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21556716" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23271494" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Cyclosporine versus mycophenolate mofetil for maintenance of remission of steroid-dependent nephrotic syndrome after a single infusion of rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25085238" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Rituximab-associated agranulocytosis in children with refractory idiopathic nephrotic syndrome: case series and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31705306" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Immunoglobulin serum levels in rituximab-treated patients with steroid-dependent nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23700173" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Fulminant viral myocarditis after rituximab therapy in pediatric nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19396468" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Fatal pulmonary fibrosis after rituximab administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24619426" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Development of antirituximab antibodies in children with nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32556955" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Unfavorable impact of anti-rituximab antibodies on clinical outcomes in children with complicated steroid-dependent nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34132894" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Anti-rituximab antibodies in pediatric steroid-dependent nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16126050" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Children with steroid-sensitive nephrotic syndrome come of age: long-term outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19808243" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30426221" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Childhood onset steroid-sensitive nephrotic syndrome continues into adulthood.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
